Corvus Pharmaceuticals Stock Plunges on Soquelitinib Trial Data
Soquelitinib shows promise in Phase 1 atopic dermatitis trial, with significant EASI score reductions observed. Despite positive efficacy and safety data, CRVS stock dropped sharply, warranting further analysis.
Corvus Pharmaceuticals Stock Plunges on Soquelitinib Trial Data Read More »